Table 3.
Summary of costs and utilities included in the model.
| Base case | DSA lower value* | DSA upper value* | PSA distribution | Source | |
|---|---|---|---|---|---|
| Annual costs of drug regimen (USD) | |||||
| Standard glucose control | 164 | 115 | 319 | Gamma | Procurement price list, Drug Administration of Vietnam |
| Intensive glucose control | 319 | 223 | 415 | Gamma | Procurement price list, Drug Administration of Vietnam |
| Health state costs (USD 2014) | |||||
| Myocardial infarction 1st year Subsequent years | 14,975 3,751 |
10,483 2,626 |
19,468 4,876 |
Gamma Gamma |
Permsuwan et al. (20) |
| Stroke 1st year Subsequent years | 10,051 3,364 |
7,036 2,355 |
13,066 4,373 |
Gamma Gamma |
Permsuwan et al. (20) |
| ESRD 1st year Subsequent years | 86,397 59,411 |
60,478 41,588 |
112,316 77,234 |
Gamma Gamma |
Permsuwan et al. (20) |
| DRED 1st year Subsequent years | 4,352 2,643 |
3,046 1,850 |
5,658 3,436 |
Gamma Gamma |
Permsuwan et al. (20) |
| Major hypoglycemia Per event | 3,885 | 2,720 | 5,051 | Gamma | Permsuwan et al. (20) |
| Health state utilities | |||||
| Population norms Baseline age (i.e., 66 years) 5 years after (i.e., 71 years) | 0.810 0.808 |
0.567 0.566 |
1.000 0.810 |
Beta Beta |
Nguyen et al. (24) |
| Events disutilities (%) | |||||
| Myocardial infarction 1st year Subsequent years | −15.9 −9.6 |
−11.1 −6.7 |
−20.6 −12.5 |
Beta Beta |
Palmer et al. (25) |
| Stroke 1st year Subsequent years | −22.2 −33.1 |
−15.6 −23.1 |
−28.9 −43.0 |
Beta Beta |
Palmer et al. (25) |
| ESRD 1st year Subsequent years | −35.5 −35.5 |
−24.9 −24.9 |
−46.2 −46.2 |
Beta Beta |
Palmer et al. (25) |
| DRED 1st year Subsequent years | −9.8 −9.8 |
−6.9 −6.9 |
−12.8 −12.8 |
Beta Beta |
Palmer et al. (25) |
| Major hypoglycemia Per event | −0.6 | −0.4 | −0.8 | Beta | Palmer et al. (25) |
*
±30% margins.
CV, cardiovascular; DRED, diabetes-related eye disease; DSA, deterministic sensitivity analysis; ESRD, end-stage renal disease; PSA, probabilistic sensitivity analysis; USD, United States Dollars.